Here's Why You Should Hold On To Varian (VAR) Stock For Now
Zacks Investment Research | Nov 24, 2019 08:42PM ET
Varian Medical Systems, Inc. (NYSE:VAR) is likely to gain from strong fourth-quarter fiscal 2019 results and a slew of positive developments. However, the company has been experiencing weakness in its Proton Therapy revenues.
In a year’s time, shares of Varian have rallied 12.1% compared with the industry ’s 11% rise. Meanwhile, the S&P 500 Index has risen 17.9%.
With a market capitalization of $11.98 billion, Varian is the world’s leading provider of radiotherapy, radiosurgery, proton therapy and brachytherapy for treating cancer and other medical conditions. The company’s earnings are anticipated to grow 8% over the next five years. For the trailing four quarters, the company has a positive earnings surprise of 1.6%, on average.
Let’s take a closer look at the factors that substantiate Varian’s Zacks Rank #3 (Hold).
Factors to Boost Varian
In the recently-reported fourth quarter, Varian posted earnings per share (EPS) of $1.21, in line with the Zacks Consensus Estimate. Adjusted EPS rose 4.3% year over year.
The company reported revenues of $878.9 million, which surpassed the consensus mark of $853.3 million. On a year-over-year basis, revenues rose 9.6% and 12% at constant currency (cc).
Notably, Oncology revenues increased 8.5% year over year and 11% at cc, driven by an expansion of the company’s net installed base. Gross orders grew 7% from the year-ago quarter to $1.1 billion.
Apart from this, Varian has seen a slew of developments of late.
For instance, South Florida Proton Therapy Institute, an International facility has treated its first patient utilizing the Varian ProBeam Compact single-room proton therapy system. Notably, Varian’s proton therapy is one of the most advanced radiation treatments available.
Earlier this month, management at Varian announced that the company has been selected as the vendor of choice by the Michigan Oncology Quality Consortium to support its efforts to develop patient-centered quality measures for cancer care.
Last month, Australia's Icon Group made a purchase order to improve the quality of cancer care treatment across its international network. The order includes a significant suite of Varian’s cancer treatment hardware and software, including a purchase of Ethos therapy, an adaptive intelligence solution.
Get The News You Want
Varian Medical Systems, Inc. Price and Consensus
.
Conmed has a long-term earnings growth rate of 17%.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through Q3 2019, while the S&P 500 gained +39.6%, five of our strategies returned +51.8%, +57.5%, +96.9%, +119.0%, and even +158.9%.
This outperformance has not just been a recent phenomenon. From 2000 – Q3 2019, while the S&P averaged +5.6% per year, our top strategies averaged up to +54.1% per year.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.